Kyowa Hakko Kirin's troubled Parkinson's disease drug istradefylline (KW-6002) is moving towards an approval filing in Japan after meeting its primary endpoint in a local Phase III study.
The firm could not say when the submission would be made, but it may lead to the first approval for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?